ArticleFrontiers in immunology2024

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

Sebastian J Schober et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.